Astrazeneca (AZN) Shares Outstanding (2009 - 2026)
Astrazeneca (AZN) posted quarterly Shares Outstanding (Entity) of $1.6 billion for Q2 2026, up 100.13% year-over-year from $775.0 million in Q2 2025, and little changed quarter-over-quarter from $1.6 billion in Q4 2025.
Astrazeneca (AZN) Shares Outstanding (2009 - 2026) Analysis & Trends
Astrazeneca's Shares Outstanding (Entity) history runs 15 years deep, the most recent figure standing at $1.6 billion for Q2 2026.
- In Q2 2026, Shares Outstanding (Entity) rose 100.13% year-over-year to $1.6 billion; the TTM figure through Jun 2026 stood at $1.6 billion (up 100.13% YoY), while the FY2025 annual figure was $1.6 billion, up 100.0% from the prior year.
- Shares Outstanding (Entity) for Q2 2026 stood at $1.6 billion, roughly flat from $1.6 billion in the prior quarter.
- The five-year high for Shares Outstanding (Entity) was $1.6 billion in Q2 2026, with the low at $774.0 million in Q4 2022.
- The 5-year median for Shares Outstanding (Entity) is $775.0 million (2023), against an average of $947.1 million.
- The sharpest annual moves came in 2024 and 2026: Shares Outstanding (Entity) changed 0.0% in 2024, then jumped 100.13% in 2026.
- Astrazeneca's Shares Outstanding (Entity) stood at $774.0 million in 2022, then rose by 0.06% to $774.5 million in 2023, then increased by 0.06% to $775.0 million in 2024, then surged by 100.0% to $1.6 billion in 2025, then gained by 0.06% to $1.6 billion in 2026.
- Business Quant data shows AZN's Shares Outstanding (Entity) at $1.6 billion in Q2 2026, $1.6 billion in Q4 2025, and $775.0 million in Q2 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Shares Outstanding (Qtr) |
|---|---|---|---|---|---|
| 1 | Johnson & Johnson | 652.20 Bn | 631.44 Bn | 17.26 Bn | 2.41 Bn |
| 2 | AbbVie | 469.51 Bn | 462.94 Bn | 12.70 Bn | 1.77 Bn |
| 3 | Merck | 376.81 Bn | 369.67 Bn | 12.21 Bn | 2.47 Bn |
| 4 | Novartis Ag | 303.04 Bn | 295.35 Bn | 11.24 Bn | 1.91 Bn |
| 5 | Astrazeneca | 257.61 Bn | 252.71 Bn | 12.86 Bn | 1.55 Bn |
| 6 | Amgen | 237.37 Bn | 223.38 Bn | 7.24 Bn | 540.00 Mn |
| 7 | Gilead Sciences | 181.73 Bn | 178.55 Bn | 6.22 Bn | 1.24 Bn |
| 8 | Pfizer | 159.66 Bn | 147.96 Bn | 10.94 Bn | 5.70 Bn |
| 9 | Gsk | 106.24 Bn | 102.07 Bn | 8.24 Bn | 2.03 Bn |
| 10 | Sanofi | 55.07 Bn | 47.69 Bn | 10.79 Bn | 1.20 Bn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 1.55 Bn |
| Mar 31, 2026 | 1.55 Bn |
| Dec 31, 2025 | 1.55 Bn |
| Sep 30, 2025 | 775.00 Mn |
| Jun 30, 2025 | 775.00 Mn |
| Mar 31, 2025 | 775.00 Mn |
| Dec 31, 2024 | 775.00 Mn |
| Sep 30, 2024 | 775.00 Mn |
| Jun 30, 2024 | 775.00 Mn |
| Mar 31, 2024 | 774.50 Mn |
| Dec 31, 2023 | 774.50 Mn |
| Sep 30, 2023 | 775.00 Mn |
| Jun 30, 2023 | 775.00 Mn |
| Mar 31, 2023 | 774.00 Mn |
| Dec 31, 2022 | 774.00 Mn |
| Sep 30, 2022 | 774.50 Mn |
| Jun 30, 2022 | 774.50 Mn |
| Mar 31, 2022 | 709.00 Mn |
| Dec 31, 2021 | 709.00 Mn |
| Sep 30, 2021 | 656.00 Mn |